Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05253846 | Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29(ShorTrip) | active not recruiting | Phase 2 | 63 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer(LOGICAN) | active not recruiting | Phase 2 | 118 | UNICANCEROTHER |
| 1 |
| Jul 24, 2026 |
| clinicaltrials |
| NCT06193733 | Dendritic Cell Vaccination to Prevent Hepatocellular Carcinoma Recurrence After Liver Resection - Phase II Clinical Trial | active not recruiting | Phase 2 | 74 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07726329 | Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 100 | Chang Gung Memorial HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT05609370 | A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 113 | BeiGeneINDUSTRY | 4 | Jul 23, 2026 | clinicaltrials |
| NCT06304974 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) | active not recruiting | Phase 3 | 497 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06982768 | How Epigenetic Changes in hMLH1 Connect Lab Research With Diagnosis in Gastric Cancer(EMBRACE-hGC) | active not recruiting | — | 245 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02298959 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | active not recruiting | Phase 1 | 59 | National Cancer Institute (NCI)NIH | 2 | Jul 22, 2026 | clinicaltrials |
| NCT02711553 | A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer | active not recruiting | Phase 2 | 309 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 22, 2026 | clinicaltrials |
| NCT03485209 | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors(innovaTV 207) | active not recruiting | Phase 2 | 350 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 22, 2026 | clinicaltrials |
| NCT03796884 | Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03822572 | ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer(ABCSG C08) | active not recruiting | N/A | 92 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04521686 | Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations | active not recruiting | Phase 1 | 200 | Eli Lilly and CompanyINDUSTRY | 9 | Jul 22, 2026 | clinicaltrials |
| NCT05771584 | Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer(Conerstone3) | active not recruiting | Phase 2 | 24 | Aston Sci. Inc.INDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05848739 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | Sapience TherapeuticsINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT06243757 | A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers | active not recruiting | — | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07340567 | Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test(CIRCULATEIII) | active not recruiting | Phase 3 | 2,450 | UNICANCEROTHER | 2 | Jul 22, 2026 | clinicaltrials |
| NCT03816358 | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2026 | clinicaltrials |
| NCT05055323 | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 20 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05114798 | Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers | active not recruiting | N/A | 194 | University of Illinois at ChicagoOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06215677 | Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer(NITDC) | active not recruiting | Phase 2 | 18 | Peking Union Medical College HospitalOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03704662 | Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma | active not recruiting | N/A | 102 | Medical College of WisconsinOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT03885817 | Physically Active During Cancer Treatment (FAKT)(FAKT) | active not recruiting | N/A | 66 | St. Olavs HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04599140 | SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial | active not recruiting | Phase 1 / Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05194293 | Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer | active not recruiting | Phase 2 | 4 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT06607185 | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | active not recruiting | Phase 1 | 750 | Eli Lilly and CompanyINDUSTRY | 8 | Jul 20, 2026 | clinicaltrials |
| NCT07522320 | Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management(EconROGCAS) | active not recruiting | — | 250 | Unidade Local De Saúde Do Norte AlentejanoOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713290 | A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma | active not recruiting | Phase 1 | 6 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04792801 | PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC(TEP CARE) | active not recruiting | — | 108 | University Hospital, LilleOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05148572 | Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma(PROSECT) | active not recruiting | — | 101 | National Cancer Centre, SingaporeOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05425940 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer(STELLAR-303) | active not recruiting | Phase 3 | 901 | ExelixisINDUSTRY | 16 | Jul 17, 2026 | clinicaltrials |
| NCT07229443 | CoGENES Randomized Controlled Trial (RCT) | active not recruiting | N/A | 138 | University of Southern CaliforniaOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711470 | Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC(SCOPE) | active not recruiting | Phase 2 | 140 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07711509 | Autologous Fecal Microbiota Transplantation for Anal Function Recovery After Ileostomy Reversal in Rectal Cancer | active not recruiting | N/A | 35 | Peking University People's HospitalOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | active not recruiting | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03599752 | Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases | active not recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03856658 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | active not recruiting | Phase 2 | 14 | Corewell Health WestOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04188145 | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer(BEVAMAINT) | active not recruiting | Phase 3 | 400 | Centre Hospitalier Universitaire DijonOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04523818 | Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma | active not recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04607590 | Yoga Program for Improving the Quality of Life in Couples Coping With Cancer | active not recruiting | N/A | 600 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05041153 | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03778957 | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma(EMERALD-1) | active not recruiting | Phase 3 | 724 | AstraZenecaINDUSTRY | 18 | Jul 15, 2026 | clinicaltrials |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2026 | clinicaltrials |
| NCT06129604 | Pilot Window of Opportunity Trial (POET) | active not recruiting | Phase 2 | 10 | University of OklahomaOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | active not recruiting | Phase 2 | 72 | Coherus Oncology, Inc.INDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT01505400 | Integrated Molecular Profiling in Advanced Cancers Trial(IMPACT) | active not recruiting | — | 3,026 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.(MEDIOLA) | active not recruiting | Phase 1 / Phase 2 | 264 | AstraZenecaINDUSTRY | 7 | Jul 14, 2026 | clinicaltrials |
| NCT03712566 | Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy(MASST) | active not recruiting | — | 39 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 24, 2026source: clinicaltrials